Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group

The Hypertension Detection and Follow-up Program (HDFP) previously described a significant reduction in five-year, all-cause mortality in its intensively treated stepped care (SC) group relative to its referred care (RC) control group. At the time this finding was described, a proportion of the SC cohort had been treated for periods as long as 6.7 years, but comparable RC and SC mortality data beyond five years were not available. These data, which are described herein, indicate that the 6.7-year life-table mortality rates were 95.1/1000 participants for SC vs 116.3/1000 participants for RC, a larger mortality difference than was observed at five years. This favorable finding for SC extended to all major subgroups, including white women and those aged 30 to 49 years at trial entry. Six months after the close of the treatment trial, a two-year posttrial surveillance study, which extended mortality follow-up to 8.3 years, was conducted. The posttrial use of antihypertensive medication declined in SC and increased in RC participants so that by the end of the posttrial period, there was little difference in the percentages of SC and RC participants taking medication. Control of blood pressure, indicated by mean diastolic blood pressure and by percent of participants with a pressure of 90 mm Hg or less, was slightly better for SC than for RC participants (SC group, 86.5 mm Hg and 68% controlled; RC group, 87.8 mm Hg and 62% controlled). The absolute mortality advantage found at 6.7 years persisted and increased throughout the posttrial period of follow-up despite discontinuation of the formal SC therapy program. It is postulated that regression of hypertensive end-organ changes brought about by the more effective SC treatment caused this favorable outcome.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

So, What's New?
Kuller
Stroke 2007;38:1427-1429.
FULL TEXT  

Diuretics Are Color Blind
Neaton and Kuller
JAMA 2005;293:1663-1666.
FULL TEXT  

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian et al.
Hypertension 2003;42:1206-1252.
ABSTRACT | FULL TEXT  

Cost as a Barrier to Medical Care in Relation to Unemployment Rates
Nelson et al.
NEJM 1998;339:1644-1645.
FULL TEXT  

Behavior and Biology: The Basic Sciences for AHA Action : Presented at the 70th Scientific Sessions of the American Heart Association November 9, 1997 Orlando, Florida
Hill
Circulation 1998;97:807-810.
FULL TEXT  

Behavior and Biology: The Basic Sciences for AHA Action : Presented at the 70th Scientific Sessions of the American Heart Association November 9, 1997 Orlando, Florida
Hill
Stroke 1998;29:739-742.
FULL TEXT  

Different Concepts in First-Line Treatment of Essential Hypertension: Comparison of a Low-Dose Reserpine-Thiazide Combination With Nitrendipine Monotherapy
Kronig et al.
Hypertension 1997;29:651-658.
ABSTRACT | FULL TEXT  

Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study
Samuelsson et al.
BMJ 1996;313:660-663.
ABSTRACT | FULL TEXT  

The number needed to treat: a clinically useful nomogram in its proper context
Chatellier et al.
BMJ 1996;312:426-429.
FULL TEXT  

Thiazides and Hypertension in the Elderly
Gifford and Kaplan
Hypertension 1995;25:1052-1052.
FULL TEXT  

Antihypertensive Therapy in Dyslipidemic Men : Effects on Coronary Heart Disease Incidence and Total Mortality
Manttari et al.
Hypertension 1995;25:47-52.
ABSTRACT | FULL TEXT  

Diuretics--Current Issues and Updates
Carasiti
Journal of Pharmacy Practice 1990;3:295-304.